Antibodies against light neurofilaments in multiple sclerosis patients

Acta Neurologica Scandinavica

Volumn 116, Issue 2, 2007, Pages 100-107

  Bartos A ^a   Fialova L ^b   Soukupova J ^b   Kukal, J ^c   Malbohan, I ^b   Pitha J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Antibody; Axonal damage; Cerebrospinal fluid; Intrathecal synthesis; Multiple sclerosis; Neurofilament

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN SUBUNIT;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROFILAMENT; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AXONS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; WALLERIAN DEGENERATION;

EID: 34547442948     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00794.x     Document Type: Article

References (18)

1. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003 206 : 165 71.
2. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002 122 : 132 9.
3. Eikelenboom MJ, Petzold A, Lazeron RH et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003 60 : 219 23.
4. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003 61 : 1720 5.
5. Norgren N, Sundstrom P, Svenningsson A et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004 63 : 1586 90.
6. Petzold A, Eikelenboom MJ, Keir G et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005 76 : 206 11.
7. Al-Chalabi A, Miller CC. Neurofilaments and neurological disease. Bioessays 2003 25 : 346 55.
8. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005 233 : 183 98.
9. Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 47 : 707 17.
10. Keegan M, Konig F, Mcclelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005 366 : 579 82.
11. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13 : 227 31.
12. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996 46 : 907 11.
13. Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50 : 121 7.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 33 : 1444 52.
15. Roxburgh RH, Seaman SR, Masterman T et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005 64 : 1144 51.
16. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977 37 : 397 401.
17. Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002 58 : 1372 81.
18. Ehling R, Lutterotti A, Wanschitz J et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004 10 : 601 6.